Objectives:

since the beginning of vaccination against SARS-CoV-2 virus one of the most frequent entities of venous thromboembolism (VTE), deep vein thrombosis (DVT), has been scarcely documented. We analyze DVT episodes during vaccination against SARS-CoV-2 period.

Material and methods:

retrospective unicenter analysis including patients diagnosed with DVT (January -September 2021). Patients were divided into two groups, vaccinated and unvaccinated against SARS-CoV-2 28 days prior to DVT symptoms onset. Primary endpoint: DVT severity (pulmonary embolism (PE) and/or hospital admission). Secondary endpoints: DVT risk factors (unprovoked, VTE antecedent, immobilization, trauma, surgery, thrombophilia, hormone therapy and cancer).

Results:

there were 192 DVT diagnoses, 42 (21,9 %) vaccinated and 150 (78,1 %) unvaccinated. DVT severity: PE: 52,4 % vaccinated vs. 62,7 % controls (p = 0,228); hospital admission: 52,4 % vaccinated vs. 62,4 % unvaccinated (p = 0,536); unprovoked DVT: 28,6 % vaccinated vs. 48 % unvaccinated (p = 0,025); VTE antecedent: 21,4 % vaccinated vs. 17,3 % unvaccinated (p = 0,543): immobilization: 7,1 % vaccinated vs. 12,7 % unvaccinated; trauma: 4,8 % vaccinated vs. 6 % unvaccinated (p = 1); surgery: 4,8 % vaccinated vs. 1,3 % unvaccinated (p = 0,209); thrombophilia: 16,7 % vaccinated vs. 4 % unvaccinaed (p = 0,009); hormone theraphy: 9,5 % vaccinated vs. 3,3 % unvaccinated (p = 0,107); cancer: 28,6 % vaccinated vs. 18,7 % unvaccinated (p = 0,162). Multivariate analysis showed a higher risk of DVT in vaccinated patients with thrombophilia, with an OR of 6,10 (95 % CI, 1,52-24,37).

Conclusion:

vaccination against SARS-CoV-2 doesn’t seem to increased DVT severity, although a higher incidence of DVT in vaccinated patients with thrombophilia was observed.

        · resumen en Español     · texto en Español     · Español ( pdf )